Reshaping the HIV treatment and prevention landscape
R&D
Differentiated R&D approach focused on the science of the immune system,
human genetics and advanced technologies
Improved pipeline and productivity in core TAs with disciplined capital allocation
Clear scientific synergies across Vaccines and Pharma
>£20bn non-risk-adjusted potential in late stage pipeline
Recent approvals and late-stage pipeline drive growth through 2031
Continued pipeline strengthening through innovative early programmes and BD
All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates.
See basis of preparation and assumptions in Appendix. Pipeline sales potential based on non-risk adjusted peak year sales. See basis of preparation and assumptions in Appendix.
Note: COVID therapeutic and vaccine solutions are excluded from the above.
TAs therapy areas; BD business development
43View entire presentation